A Random Approach to the Determination of Amino Acid Pairs in Von Hippel-Lindau Disease Tumor Suppressor (G7 Protein)

Journal of Applied Research

Volumn 3, Issue 4, 2003, Pages 512-520

  Wu, G ^a   Yan, S M ^a  

^a DreamSciTech Consulting   (China)

Author keywords

G7 protein; Probability; Randomness; Von Hippel Lindau disease

Indexed keywords

AMINO ACID; G7 PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ARTICLE; GENE; GENE MUTATION; POINT MUTATION; PROTEIN ANALYSIS; RANDOMIZATION; VON HIPPEL LINDAU DISEASE; VON LIPPEL LINDAU GENE;

EID: 2342608968     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Maher ER, Yates JR, Harries R., et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 1990;77:1151-1163.
2. Singh AD, Shields CL, Shields JA. Von Hippel-Lindau disease. Surv Ophthalmol. 2001;46:117-142.
3. Hes FJ, van der Luijt RB, Lips CJM. Clinical management of Von Hippel-Lindau (VHL) disease. Neth J Med. 2001;59:225-234.
4. Maher ER, Iselius L, Yates JR, et al. Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991;28:443-447.
5. Neumann HP, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet. 1991;337:1052-1054.
6. Neumann HPH. Pheochromocytomas multiple endocrine neoplasia type 2 and von Hippel-Lindau disease. N Eng. J Med. 1994:330:1091-1092.
7. Moller HU. Familial angiomatosis retinae et cerebelli. Acta Ophthalmol (Copenh). 1929;7:244-260.
8. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988;332:268-269.
9. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317-1320.
10. Hes FJ, Lips CJM, van der Luijt RB. Molecular genetic aspects of Von Hippel-Lindau (VHL) disease and criteria for DNA analysis in subjects at risk. Neth J Med. 2001;59:235-243.
11. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutat. 1998;12:417-423.
12. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlation with phenotype. Hum Mutat. 1995;5:66-75.
13. Maxwell PH, Wiesener MS, Chang GW. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275.
14. Kaelin WG Jr. Cancer. Many vessels, faulty gene. Nature. 1999;399:203-204.
15. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820-823.
16. Chang JH, Spraul CW, Lynn ML, et al. The two-stage mutation model in retinal hemangioblastoma. Ophthalmic Genet. 1998;19:123-130.
17. Maher ER, Yates JR, Ferguson-Smith MA. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet. 1990;27:311-314.
18. Zber B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature. 1987;327:721-724.
19. Kreusel KM, Bornfeld N, Lommatzsch A, et al. Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma. Ophthalmology. 1998;105:1386-1392.
20. Rideout WM, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in human LL receptor and p53 genes. Science. 1990;249:1288-1290.
21. Montesano R., Hainaut P, Wild CP. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst. 1997;89:1844-1851.
22. Hainaut P, Pfeifer GP. Patterns of p53 GæT transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis. 2001;22:367-374.
23. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 1994;13:3496-3504.
24. Forrester K, Lupold SE, Ott VL, Chay CH, Band V, Wang XW, et al. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 1995;10, 2103-2111.
25. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug, JE, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996;2:811-814.
26. Wu G, Yan SM. Prediction of presence and absence of two- and three-amino-acid sequence of human monoamine oxidase B from its amino acid composition according to the random mechanism. Biomol. Eng. 2001;18:23-27.
27. Bairoch A, Apweiler R. The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 2000. Nucleic Acids Res. 2000;28:45-48.
28. Wu G, Yan SM. Randomness in the primary structure of protein: methods and implications. Mol Biol Today. 2002;3:31-37.
29. Feller W. An Introduction to Probability Theory and Its Applications. Vol I. 3rd ed. New York: John Wiley and Sons; 1968.